Stephen K. Brannan
CIK 1777631 · Chief Medical Officer · last filed 2025-11-10
Stephen K. Brannan is a Chief Medical Officer who has filed 39 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing, for SER, was dated Nov 10, 2025. Across all open-market trades the lifetime net is −$40.3M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
39
-$40.28M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SER | Director | — | $1.84 | — | $0 | 2 | 2025-11-10 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | Chief Medical Officer | 6,487 | $329.83 | $2.14M | -$40.28M | 37 | 2024-03-18 |
Recent Filings
39 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-11-10 | SER | Grant (A) | — | $0 | EDGAR |
| 2025-06-17 | SER | Grant (A) | — | $0 | EDGAR |
| 2024-03-18 | Karuna Therapeutics, Inc. (KRTX) Delisted | Disp (D) | −42,604 | -$14.06M | EDGAR |
| 2024-03-11 | Karuna Therapeutics, Inc. (KRTX) Delisted | Mixed | +2,500 | -$955.1K | EDGAR |
| 2024-02-15 | Karuna Therapeutics, Inc. (KRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-12 | Karuna Therapeutics, Inc. (KRTX) Delisted | Mixed | +1,454 | -$1.34M | EDGAR |
| 2024-01-09 | Karuna Therapeutics, Inc. (KRTX) Delisted | Mixed | +2,500 | -$2.95M | EDGAR |
| 2023-12-12 | Karuna Therapeutics, Inc. (KRTX) Delisted | Mixed | +2,500 | -$693.7K | EDGAR |
| 2023-11-13 | Karuna Therapeutics, Inc. (KRTX) Delisted | Mixed | +2,500 | -$217.4K | EDGAR |
| 2023-10-10 | Karuna Therapeutics, Inc. (KRTX) Delisted | Mixed | +2,500 | -$194.4K | EDGAR |